




Characterization of endorphin gene expression following electroporation in mice
tibialis anterior muscle
implications for gene doping detection
Nøhr, Morten Klitgaard; Gazerani, Parisa; Gehl, Julie; Lichota, Jacek
Published in:




Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Nøhr, M. K., Gazerani, P., Gehl, J., & Lichota, J. (2015). Characterization of endorphin gene expression
following electroporation in mice tibialis anterior muscle: implications for gene doping detection. International
Journal of Sports and Exercise Medicine, 1(1), [003]. http://clinmedjournals.org/articles/ijsem/ijsem-1-003.pdf
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
International Journal of
Sports and Exercise Medicine
Research Article: Open Access
C l i n M e d
International Library
Citation: Nohr MK, Gazerani P, Gehl J, Lichota J (2015) Characterization of Endorphin 
Gene Expression Following Electroporation in Mice Tibialis Anterior Muscle: Implications 
for Gene Doping Detection. Int J Sports Exerc Med 1:003
Received: March 16, 2015: Accepted: April 10, 2015: Published: April 13, 2015
Copyright: © 2015 Nohr MK. This is an open-access article distributed under the terms of 
the Creative Commons Attribution License, which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Nohr et al. Int J Sports Exerc Med 2015, 1:1
Characterization of Endorphin Gene Expression Following 
Electroporation in Mice Tibialis Anterior Muscle: Implications for Gene 
Doping Detection
Morten Klitgaard Nohr1, Parisa Gazerani1,2*, Julie Gehl3 and Jacek Lichota1
1Section of Biomedicine, Department of Health Science and Technology, Aalborg University, Denmark
2Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Denmark
3Center for Experimental Drug and Gene Electrotransfer, Department of Oncology, Copenhagen University Hospital 
Herlev, Denmark
*Corresponding author: Parisa Gazerani, Pharm D, PhD, Department of Health Science and Technology, Aalborg 
University, Frederik Bajers Vej 7D3, 9220 Aalborg East, Denmark, Tel: (+45) 9940 2412, Fax: (+45) 9815 4008, 
E-mail: gazerani@hst.aau.dk 
Introduction
Since ancient time, doping has been used by athletes for a better 
chance of winning. The prevalence has been increasing since, thus 
showing the willingness athletes possess for using performance-
enhancing agents. In the professional sports a total of 66 % was 
excluded by the U.S. Anti-Doping Agency (USADA) because of the 
use of doping [1], and 3% of the non-professional fitness users have 
either used or use anabolic steroids [2].
Different types of performance-enhancing agents are used 
in different branches of sports, e.g. erythropoietin is widely used 
in cycling and testosterone in weightlifting competitions. The 
world’s anti-doping agency (WADA) has therefore formed a list of 
doping agents, which contains all substances and methods that can 
potentially be used as performance-enhancing agents. On this list a 
relatively new doping method has been added, which is gene doping. 
This is a technique, in which a gene of interest is inserted into either 
the cell nucleus transiently or even permanently in the genome of 
the athlete [3]. The inserted gene is capable of producing the desired 
protein, thus the gene doping user may receive the same effect as 
using conventional doping, but with a reduced risk of efficient 
detection and thus disqualification.
In order to insert a gene, different methods have been applied. 
One of these is called electroporation [4] and exhibits potential as a 
method for gene doping.
In a recent study, the researchers showed that plasmid DNA 
encoding erythropoietin (EPO) could successfully be transfected into 
muscle in mice and rats, and skin in mice [5,6]. This was confirmed 
by measuring the levels of EPO in blood samples. The results showed 
an increase in EPO, which reached to the desirable therapeutic level 
[5,6]. This indicates that it is possible to insert a gene of interest and 
obtain a measurable effect, which could be a therapeutic method for 
helping patients with protein deficiencies.
In addition to EPO, a number of other genes could potentially be 
applied for doping purposes. One of the potential candidates would 
be insertion of a gene that encodes enkephalins. The effect would 
contribute to a higher pain tolerance while performing heavy sports 
related tasks. Enkephalins are neuropeptides, which bind to opioid 
receptors in the nervous system, causing analgesic effects [7]. This 
was confirmed by a study conducted by JR. Goss et al, which showed 
that an inserted gene encoding PENK into dorsal root ganglion of 
rats exerted an analgesic effect [8]. Therefore, the evidence is clear 
for a method of treating pain, but also way of suppressing pain under 
exercise. It is only a matter of time before athletes could undertake this 
new doping method by a proper pain reducing gene and application 
of an effective transfection method.
Abstract
Since ancient time, doping has been used by athletes. The 
prevalence for using performance-enhancing agents is increasing 
and new methods are being applied. Gene doping is foreseen to 
become one of the new doping methods in athletic performances. 
This study was therefore performed to investigate the possibility 
of transfecting a gene encoding the endogenous peptide 
preproenkephalin (PENK) in mice as gene doping candidate and 
subsequently establish a functional detection method. This was 
performed using the blood and muscle as samples mimicking 
the most plausible detection method to be used in real life. Our 
results showed that it is possible to transfect PENK into mice and 
subsequently detect it. However, it was only possible to detect 
PENK in the blood after 24 hours and in the muscle after 48. This 
therefore illustrates the trouble in detecting the use of gene doping, 
as the blood sample must be acquired no longer than 24 hours after 
transfection. The gene doping detection method must therefore be 
implemented as a normal routine check, if the antidoping agencies 
have a chance against the athlete’s willingness to use doping. 
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Therefore, the antidoping agencies should consider acquiring a 
technique of detecting of this doping method.
Electroporation based gene delivery is now in experimental use 
for the treatment of e.g. cancer [9].
The present study is focusing on the insertion of a gene 
encoding preproenkephalin (PENK) into muscle cells of mice, and 
subsequently attempting to detect this gene in the blood and muscles 
by quantitative polymerase chain reaction (qPCR). The transfection 
method is electroporation, as this is the most possible method for 
athletes to use due to its safety and efficiency [10].
Materials and Methods
Animals
All animal experiments were conducted in agreement with the 
recommendation of the European Convention for the protection of 
Vertebrate Animals used for Experimentation. The experiments were 
approved by the animal ethics committee (2013-15-2937-00760) and 
performed at Herlev Hospital, Denmark. A total of sixteen, 6-8 weeks 
old female C57BL/6 mice were used.
The animals were bred at Herlev Hospital, and maintained in a 
thermo-stated environment under a 12-hour light/dark cycle and had 
free access to food and drinking water.
Plasmid and transformation
The plasmid used in this experiment was purchased from Origene, 
USA (Cat. MG203555). The plasmid contained the sequence encoding 
fusion protein with mouse PENK (pubmed ref: NM_001002927.2) 
in frame with green-fluorescent protein (GFP) thereby enabling 
visualization of a successful transfection and subcellular localization 
of PENK.
The plasmid was transformed by heat-shock into the chemically 
competent E. coli strain DH5α (Invitrogen, USA), and plated onto 
an agar plate containing 100μg/ml ampicillin. Bacteria were then 
incubated for 24 hours, resulting in the formation of colonies. One 
colony was used to propagate and purify the necessary amount of 
plasmid by a plasmid purification kit, NucleoSpin Midi (Machery-
Nagel, Germany) for further experiments.
In vitro experiment
Cell culture: C2C12 myoblast cells (ATCC, USA) were cultivated 
in medium consisting of DMEM (Sigma Aldrich, USA) with 10 % 
fetal calf serum (Gibco, USA) and 1 % penicillin/streptomycin (Gibco, 
Cat. No. 15140-122). Cells were grown in T175 culture flask. When 
cell confluence reached 60-70 %, cells were trypsinized and washed 
twice with sterile PBS. The cells were counted on a hemocytometer 
(Assistant, Germany) and passage into a new flask with fresh medium.
Chemical transfection: When 50% of cell confluence was 
reached the cells were trypsinized, counted and seeded into a 6-well 
culture plate at 2500 cells/cm2. Cells were then allowed to reach 
a confluence of 70–90% (24 hours), before transfection with the 
Turbofect® transfection reagent (Thermo Scientific, USA). This step 
was performed using 2μg plasmid DNA according to manufacurer’s 
protocol. Control wells were handled likewise with the exception of 
Turbofect® transfection reagent (Thermo Scientific, USA).
The transfection rate was calculated as percentage of transfected 
cells/total number of cells on five representative pictures taken from 
the same transfection.
Confocal microscopy: After visual confirmation of transfection 
using inverted fluorescent microscope (Axiovert 40, Carl Zeiss 
Microscopy, Germany) , the cells were trypsinized, resuspended 
and seeded into a chamber slide (C6307, Sigma-Aldrich, USA). The 
cells were then left for 4 hours, allowing them to attach to the glass 
slide. They were then fixed with 4% paraformaldehyde, and stained 
with 4’,6-diamidino-2-phenylindole (DAPI) . Hereafter, cells were 
visualised on a confocal microscopy (LSM 700, Carl Zeiss Microscopy, 
Germany).
In vivo experiment
Mice (n=16) were anaesthetised 15 min prior to electroporation 
by injection of 100µL of Hypnorm/Midazolam combination 
(2,5ml hypnorm/2,5ml Midazolam mixed with 5ml sterile water) 
subcutaneously. 20μl of plasmid solution (containing 10μg plasmid) 
was injected intramuscularly, using a 29G insulin syringe, into the 
musculus tibialis anterior. After the injection a plate electrode with 
a 4mm gap in between were fitted around the leg, which was shaved 
beforehand. Electrode gel was applied to ensure sufficient contact. 
A control group received 20μl of sterile saline injection instead of 
plasmid solution.
The electric field was applied using the Cliniporator (IGEA, 
Italy), which applied a combination of a High voltage pulse (800V/
cm (applied voltage=320V), 100μs) and a low voltage pulse (100V/cm 
(applied voltage=40 V), 400μs) with a 1 sec pause between pulses [6]. 
RNA extraction and qPCR analysis: The mice were euthanized 
by quick cervical dislocation, followed by decapitation and blood was 
collected in EDTA-containing eppendorf tubes. The right musculus 
tibialis anterior were removed and quickly frozen in liquid nitrogen.
Total RNA was extracted from 1ml whole blood samples 
using QIAamp RNA blood mini kit (Qiagen, Germany). The RNA 
concentration was measured using Nanophotometer (Implen, 
Germany).
Total RNA was extracted from 30mg muscle samples using 
AllPrep DNA/RNA Mini kit (Qiagen, Germany) or RNeasy Fibrous 
Tissue mini kit (Qiagen, Germany) according to the manufacturer’s 
protocol. All muscle tissue was homogenized in liquid nitrogen using 
pestle and mortar.
cDNA synthesis was performed using the RevertAidTM Premium 
First Strand cDNA synthesis kit (Thermo Scientific, USA). This was 
done using the provided oligo (dT)18 and random hexamer primers 
following protocol by the manufacturer.





qPCR was performed using 1µl cDNA, 10µL Brilliant SYBR Green 
qPCR Master mix (Agilent Technologies, Denmark) and 0,4µM of 
each primer. qPCR was done using MX3000P® instrument (Agilent 
Technologies, Denmark). All samples were run in duplicates.
Water and RT- samples were used as negative controls.
The thermal profile for qPCR was 1×: 95°C 10 min; 40×: 95°C 30 
sec, 61°C 10 sec, 70°C 30 sec; 1×: 95°C 1 min, 55°C 30sec, 95°C 30sec
Statistics
All PENK expression data were normalised to β-actin, and the data 
are presented as fold to this. Statistical analysis and visual presentation 
were performed using GraphPad Prism (GraphPad Software, USA). 
Kruskal-Wallis test followed by multiple comparisons between the 
individual groups was performed. The error bars in figure 2 and 3 
represent SEM. p values less than 0.05 was considered significant.
Results
To evaluate if the PENK plasmid could be efficiently expressed in 
muscle cells, C2C12 cells were transfected with a plasmid expressing 
PENK fused with green fluorescent protein (GFP). As indicated in 
Figure 1, GFP-PENK and DAPI positive cells were observed, and 
were found in the same focal plane. DAPI allows visualization of the 
nuclei of cells and was used to estimate the ratio between successfully 
transfected cells and non-transfected cells.
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Small vesicles with an intense GFP signal were localised in the 
peripheries of the cells, indicating that the GFP-PENK fusion protein 
resides in secretory granules as is the case with the native PENK-
protein. The overall expression efficiency was determined to be 7%.
PENK transgene expression in muscle
To determine if PENK transgene could be detected in the blood 
and muscle sixteen C57BL/6 mice were transfected by electroporation 
with the same plasmid as in the in vitro experiment. Mice were 
decapitated after 24 and 48 hours and the blood as well as the right 
quadriceps muscle were collected. The PENK gene expression in the 
muscle was investigated by qPCR (Figure 2) showing a mean value 
of 0.0471*10-2 for control, 0.08805 *10-2 for 24 hours and 1*10-2 for 
48 hours. The 24 hours group showed 1.868 times higher expression 
compared to control and 21.21 times higher after 48 hours. PENK 48 
was 11.35 higher than PENK 24. The Kruskal-Wallis resulted with a 
p-value of 0.0297 between groups. There was a significant difference 
between the control group vs. 48 hours (p=0.0162).
PENK transgene expression detected in blood samples
The same gene expression analysis was done for the blood samples. 
This was to test whether the GFP-PENK transgene is detectable in the 
whole blood after muscle electroporation. As shown in Figure 3, the 
mean value for PENK gene expression is 0.009297*10-2 for the control, 
0.0713*10-2 for 24 hours and 0.005456*10-2 for 48 hours. The 24 hours 
group showed 7.67 times higher expression compared to control 
and 0.58 times lower after 48 hours. PENK 24 was 13.07 higher than 
PENK 48. The Kruskal-Wallis test showed a p-value of 0.0035 between 
groups. There was a significant difference between the control group 
vs. 24 hours (p=0.0228) and 24 hours vs. 48 hours (p=0.0120).
Discussion
Doping remains a major challenge, and the number of athletes 
and novices being disqualified from sport competitions due to 
illegal agents [2], illustrates the importance for an effective and easy 
detection method. In this study, we show that it is possible to transfect 
a gene doping candidate (PENK) into the muscle of of mice, using 
electroporation. and subsequently a method for detecting this illicit 
gene in blood.
Cultured C2C12 muscle cells were used in the first place to validate 
the plasmid and define subcellular localisation of GFP-PENK fusion 
protein. GFP expression was observed in C2C12 cells transfected with 
the GFP-PENK plasmid. GFP signal was visible in small clusters, close 
to the cell membrane, which suggests that the fusion protein is located 
          
Figure 1: C2C12 myoblast cells stained with DAPI (A) and transfected with plasmid expressing the fusion protein GFP-PENK (B). Green fluorescent light 
illustrates the GFP-PENK fusion protein and the blue colour presents the cells stained with DAPI. The fusion protein is localized in small vesicles near the 
periphery of the cell (C), which is expected as PENK secreted into the blood
          
Figure 2: PENK gene expression in the muscle. The graph shows mean 
values for PENK gene expression as 0.0471*10-2 for control, 0.08805*10-2 for 
24 hours, and 1*10-2 for 48 hours. The Kruskal-Wallis test revealed a significant 
difference between the groups (p=0.0297). There was a significant difference 
between the control group and 48 hours (p=0.0162). However, there was no 
significant difference between control group vs. 24 hours (p=0.0727) or 24 
hours vs. 48 hours (p=0.3429). Error bars indicate SEM and grey dots show 
the individual data points. * represents p<0.05.
          
Figure 3: PENK gene expression in the blood. The graph shows mean values 
for PENK gene expression as 0.009297*10-2 for the control, 0.0713*10-2 for 
24 hours, and 0.005456*10-2 for 48 hours. The Kruskal-Wallis test revealed a 
significant difference between the groups (p=0.0035). There was a significant 
difference between control group vs. 24 hours (p=0.0228) and 24 hours vs. 48 
hours (p=0.0120). There was no significant difference between control vs. 48 
hours (p=0.4606). Error bars indicate SEM and grey dots show the individual 
data points. * represents p<0.05.
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in vesicles or secretory granules. This corresponds with the fact that 
PENK normally is secreted from cells [11]. Transfection efficiency 
was estimated to be 7 %, which was lower than reported by others (60 
- 80 %) [12]. However, the goal of this experiment was to confirm that 
GFP-PENK could be expressed in muscle cells, and since a clear GFP 
expression was seen, the low transfection efficiency in this experiment 
was not an issue. These data indicate that it is possible to transfect 
plasmid in the muscle cells, and make them produce GFP-PENK 
fusion protein. The modern doping methods can easily move into 
direction of gene-transfer, as the technology is available and relatively 
simple. The reason for choosing electroporation in the project is the 
fact that chemical transfection method will be troublesome to use as 
a doping method in vivo in contrary to electrotransfer [13]. Some 
studies indicate that the success rate of chemical transfection in vivo 
is very low, which can be due to many factors including nucleic acid/
chemical ratio, solution pH and cell membrane conditions [14]. On 
the other hand, this kind of transfection method offers a reliable 
transfection method for in vitro experiments.
In our in vivo muscle transfection model the GFP-PENK 
expression was 1.868 fold higher 24 hours post-transfection compared 
to control muscle and 21.21 fold higher 48h post-transfection. The 
statistical analysis showed a significant difference between the groups. 
These findings correlate with previous studies, showing it is possible 
to transfect and obtain sufficient transcription after gene insertion 
using electroporation as transfection method [6].
These findings suggest that the transcription of GFP-PENK in 
the transfected muscle maintains at least for 48 hours, which means 
that it is possible to detect a transgene of interest in the muscle of 
gene doping suspects, even with small amount of analysis material. 
A previous study indicates that inserted transgene in the muscle 
was still being transcribed and translated into proteins months 
after electroporation [6]. The problem for the anti-doping agencies 
would be to locate the transgenic muscle cells [15], with the lack of 
cooperation from the athlete.
After a successful transfection and expression of the transgene it 
was interesting to investigate the possibility of transgene detection 
in the blood. The hypothesis was that during electroporation some 
portion of the blood must be co-transfected with the muscle, and with 
a potential leak of blood from the transfected muscle, it is possible 
to detect the transgenic agents in a blood sample. If that is the case 
and the transgene is detectable in the blood it would make a detection 
method far easier. According to our findings it is possible to detect 
GFP-PENK fusion gene expression in the blood 24 hours after 
electroporation. However the expression drops dramatically already 
48 hours after electroporation.
The transgene needs to be transfected into the leukocytes for an 
efficient expression. However, mature white blood cells have a half-
life of 7 hours [16], and might therefore perish before the transgene 
expression can be detected. The possibility of detecting the transgenic 
cells is therefore troublesome after 48 hours, which indicates that the 
antidoping agencies must require a blood sample from the athletes 
within 24 hours after the use of gene doping if the gene doping should 
be detectable in the blood sample.
As mentioned earlier the insertion of the gene encoding 
erythropoietin (EPO) using electroporation as transfection method, 
has been capable of producing a therapeutic effect [6,15]. The same 
result has to be confirmed with PENK, before this gene can be fully 
classified as a gene doping candidate. In addition to this it would 
be necessary to establish a dose-response curve on the amount of 
plasmid encoding PENK and the PENK protein produced to obtain a 
significant analgesic effect in the athlete’s muscle.
However, if higher amounts of plasmid are required to produce 
a desirable analgesic effect, this could cause toxicity problems for the 
survival of the transfected cells [17]. According to a study by Chuang 
et al. [18] 40μg of PENK plasmid was enough to produce an analgesic 
effect in rats, therefore is seems that high amounts are needed to 
produce pain relief [19].
Previous studies indicate that it is of pivotal importance to use an 
efficient transfection method when inserting a gene into the genome 
[3]. This study is therefore offering a real method of inserting a gene of 
interest, but also an effective method of transgene detection in the blood 
sample. The evidence is therefore strong that gene doping is a real risk, 
but the results of this study propose a method of the doping detection.
Electroporation is the most plausible gene doping method, 
compared the other transfection methods. According to other studies, 
electroporation provides a safe and efficient method for the insertion 
of a gene of interest into muscle cells [5,6,15]. According to the findings 
of this study [15], only cells directly within the electrical field would be 
transfected. The chemical transfection reagents on the contrary offer high 
transfection efficiency, but their action is not localized to a specific tissue, 
which could lead to unwanted side effects [20]. Viral vectors are capable 
of integrating the gene of interest into the genome [21]. However, with 
viral transduction the transcription can become stable and therefore 
securing a more permanent gene doping effect [8]. On the contrary, 
viral transduction will cause an immune response and the production 
of antibodies [22], which can serve as another detection method. 
Concluding, many different methods have been applied as effective gene 
delivery tools but the question remains, which method will be used in 
the real life. The most successful method will most probably ensure the 
longest duration of expression of the transgenic material. As Hojman 
et al. [5] showed the transgenic EPO gene was producing a therapeutic 
effect after 42 days post-transfection, which means that a gene doped 
athlete would need a “booster” of the transgenic materiel for maintenance 
of the beneficial effect.
Conclusion
This study indicates that it is possible to transfect plasmid encoding 
GFP-PENK into the muscle and achieves a stable expression for 48 hours. 
It was also possible to detect the transgene in the muscle tissue up to 48 
hours after transfection whereas in the blood sample the duration of 
transgene expression was limited to 24 hours posing a challenge for anti-
doping agencies. Henceforth, it is impossible to locate the transfection 
site, and detect the illegal gene in the blood, this gene doping method may 
revolutionise the sport community negatively.
Acknowledgements
We would like to thank Jesper Franch and Pascal Madeleine for their 
contribution in application for funding for this study. We also thank the staff and 
members of the oncology section and associated laboratories, especially Stine Krog 
Frandsen and Anne Boye at Herlev hospital for their excellent assistance. Technical 
assistance from Jeppe Lund Nielsen from Department of Biotechnology, Chemistry 
and Environmental Engineering for confocal microscopy is highly appreciated. This 
project has been carried out with the support of Anti-Doping Denmark.
References
1. AGENCY, USADA. [http://www.usada.org/testing-statistics] 
2. Anti Doping Danmark (2013) Forside.
3. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, et al. (2004) Detection 
of integration of plasmid DNA into host genomic DNA following intramuscular 
injection and electroporation. Gene Ther 11: 711-721.
4. Bodles-Brakhop AM, Heller R, Draghia-Akli R (2009) Electroporation for the 
delivery of DNA-based vaccines and immunotherapeutics: current clinical 
developments. Mol Ther 17: 585-592.
5. Hojman P, Gissel H, Gehl J (2007) Sensitive and precise regulation of 
haemoglobin after gene transfer of erythropoietin to muscle tissue using 
electroporation. Gene Ther 14: 950-959.
6. Gothelf A, Hojman P, Gehl J (2010) Therapeutic levels of erythropoietin (EPO) 
achieved after gene electrotransfer to skin in mice. Gene Ther 17: 1077-1084.
7. Anna Baoutina, Ian E Alexander, John EJ Rasko, Kerry R Emslie (2007) 
Potential use of gene transfer in athletic performance enhancement. Mol Ther 
10: 1751–1766.
8. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, et al. (2001) Antinociceptive 
effect of a genomic herpes simplex virus-based vector expressing human 
proenkephalin in rat dorsal root ganglion. Gene Ther 8: 551-556.
9. Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, et al. (2013) Gene 
electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in 
disseminated melanoma: safety and efficacy results of a phase I first-in-man 
study. Hum Gene Ther Clin Dev 24: 99-107.
• Page 5 of 5 •Nohr et al. Int J Sports Exerc Med 2015, 1:1
10. Terova G, Rimoldi S, Bernardini G, Saroglia M (2013) Inhibition of myostatin 
gene expression in skeletal muscle of fish by in vivo electrically mediated 
dsRNA and shRNAi delivery. Mol Biotechnol 54: 673-684.
11. Hall J. E (2011) Textbook of medical physiology (12th edn).
12. TurboFect Transfection Reagent (2013) Thermo Scientific.
13. Kee ST, Gehl J, Lee EW (2011) Clinical Aspects of Electroporation.
14. Tae Kyung Kim, James H. Eberwine (2010) Mammalian cell transfection: the 
present and the future. Anal Bioanal Chem 397: 3173-3178. 
15. Spanggaard I, Corydon T, Hojman P, Gissel H, Dagnaes-Hansen F, et al. 
(2012) Spatial distribution of transgenic protein after gene electrotransfer to 
porcine muscle. Hum Gene Ther Methods 23: 387-392.
16. Walker HK, Hall WD, Hurst JW (1990) Clinical Methods The History, Physical, 
and Laboratory Examinations. 3rd Edition Butterworth Publishers USA.
17. Lundsted D (2012) Trypsin-induced VEGF expression in adipose-derived 
stem cells; optimization of assays. 
18. Chuang IC, Jhao CM, Yang CH, Chang HC, Wang CW, et al. (2004) 
Intramuscular electroporation with the pro-opiomelanocortin gene in rat 
adjuvant arthritis. Arthritis Res Ther 6: R7-7R14.
19. Chuang YC, Yang LC, Chiang PH, Kang HY, Ma WL, et al. (2005) Gene 
gun particle encoding preproenkephalin cDNA produces analgesia against 
capsaicin-induced bladder pain in rats. Urology 65: 804-810.
20. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, et al. (1994) 
Enhanced gene delivery and mechanism studies with a novel series of 
cationic lipid formulations. J Biol Chem 269: 2550-2561.
21. Gonçalves MA (2005) Adeno-associated virus: from defective virus to 
effective vector. Virol J 2: 43.
22. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, et al. 
(1997) Transduction by adeno-associated virus vectors in the rabbit airway: 
efficiency, persistence, and readministration. J Virol 71: 5932-5941.
